Comparing a new camera method to traditional imaging for thyroid cancer treatment
Comparison of a 3D Recording in a VERITON-CT™ Camera to the Anger Camera Procedure in Patients Treated by Iodine 131 for a Thyroid Cancer
NA · Central Hospital, Nancy, France · NCT05713123
This study is testing a new camera method to see if it can replace the traditional imaging for thyroid cancer patients receiving iodine 131 treatment, making the process quicker and more comfortable.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 77 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France (other) |
| Locations | 1 site (Vandœuvre-lès-Nancy) |
| Trial ID | NCT05713123 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate whether a new imaging technique using the VERITON-CT™ camera can effectively replace the traditional Anger camera procedure for patients with thyroid cancer treated with iodine 131. Participants will receive an iodine 131 capsule, and after three days, a whole-body SPECT/CT scan will be performed to assess thyroid remnants and potential metastases. The goal is to determine if the new method provides equivalent information in a shorter time frame, enhancing patient comfort and efficiency in diagnosis.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with a confirmed diagnosis of thyroid cancer who are scheduled to receive iodine 131 treatment.
Not a fit: Patients with known allergies to iodine 131, unstable medical conditions, or those unable to remain still during imaging may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to quicker and more efficient imaging procedures for thyroid cancer patients, improving their overall treatment experience.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in improving imaging techniques for cancer detection, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients over the age of 18, who have understood and signed the informed consent form. 2. Person suffering from thyroid cancer and for whom the multidisciplinary meeting has validated a treatment by iodine 131 (1100 MBq or 3700 MBq). 3. Person with no contraindication to carrying out the examination. 4. Person affiliated to a social security scheme. Exclusion Criteria: 1. Person with a known allergy to one of the components of the radiopharmaceutical (Iodine 131 capsule). 2. Pregnant woman or woman of childbearing age and without suitable contraceptive means, or breastfeeding mother. 3. Person whose medical condition is unstable and/or unable to remain still in the supine position during recordings. 4. Person deprived of liberty by a judicial or administrative decision. 5. Person of full age subject to a measure of legal protection (guardianship, curators, safeguard of justice). 6. Adult person unable to express his consent and who is not the subject of a legal protection measure.
Where this trial is running
Vandœuvre-lès-Nancy
- Chru Nancy Brabois — Vandœuvre-lès-Nancy, France (RECRUITING)
Study contacts
- Principal investigator: Elodie CHEVALIER, MD — CHRU Nancy
- Study coordinator: Véronique ROCH, MSc
- Email: v.roch@chru-nancy.fr
- Phone: 0383154276
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Device, Iodine 131, Thyroid cancer, Camera CZT